期刊文献+

达沙替尼治疗慢性髓性白血病导致可逆性肺动脉高压一例并文献复习 被引量:13

Reversible pulmonary arterial hypertension related to dasatinib in the treatment for chronic myelogenous leukemia: a case report and literature review
原文传递
导出
摘要 目的 探讨达沙替尼治疗相关肺动脉高压的临床特点及转归.方法 对1例达沙替尼治疗过程中出现肺动脉高压患者的临床特点进行分析,并系统复习相关文献.结果 1例23岁女性慢性髓性白血病患者伊马替尼治疗失败后采用达沙替尼140 mg/d治疗,获得持续的完全细胞遗传学反应.达沙替尼治疗35个月出现活动后呼吸困难,心电图提示有心室肥大、心电轴右偏;超声心动图示左心房室内径缩小,左心收缩功能正常,右心房室内径扩大,主肺动脉扩张,肺动脉压力升高为114mmHg(1 mmHg=0.133 kPa);胸部CT示肺动脉干及左右肺动脉增粗.考虑达沙替尼治疗相关肺动脉高压,停用达沙替尼后临床症状迅速缓解,停药7个月后患者心内结构以及肺动脉压力恢复正常.结论 肺动脉高压是达沙替尼治疗中少见的并发症,应当重视治疗期间心脏结构和心功能状态的监测,一旦出现肺动脉高压立刻停用并禁止再次使用达沙替尼. Objective To study the clinical features and prognosis of pulmonary arterial hypertension associated with dasatinib.Methods To present a case of pulmonary arterial hypertension (PAH) associated with long-term exposure to dasatinib and review the related literatures.Results A 23-year-old female with chronic myelogenous leukemia was treated with dasatinib at a dosage of 140 mg/d after failure of imatinib treatment and achieved complete cytogenetic response.The patient was presented with exertional dyspnea after 35 months of administration with dasatinib.The electrocardiogram showed right ventricular hypertrophy and right axis deviation; transthoracic Doppler echocardiography documented a reduction in diameters of left heart chambers with normal systolic left ventricular function,right heart chambers and pulmonary trunk dilatation,an estimated pulmonary arterial pressure of 114 mmHg;Computed tomography showed thickened pulmonary artery.PAH related to dasatinib was diagnosed and dasatinib was permanently discontinued.The symptom of dyspnea disappeared quickly after withdrawal of dasatinib.The heart structure and pulmonary arterial pressure completely recovered after 7 months of dasatinib discontinuation.Conclusions PAH is a rare adverse effect of dasatinib treatment.Echocardiograhpy,as a non-invasive screening test for PAH,should be performed before starting dasatinib treatment and repeated during the administration with dasatinib.Dasatinib should be withdrawn permanently in patients with PAH.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2014年第7期581-586,共6页 Chinese Journal of Hematology
关键词 白血病 髓系 慢性 BCR-ABL阳性 达沙替尼 高血压 肺性 Leukemia, myelogenous, chronic, BCR-ABL positive Dasatinib Hypertension,pulmonary
  • 相关文献

参考文献24

  • 1Fullmer A, Kantarjian H, Cortes J, et al. Dasatinib for the treat- ment of chronic myeloid leukemia IJl. Expert Rev Hematol, 2011, 4(3):253-260.
  • 2黄晓军,胡建达,李建勇,金洁,孟凡义,沈志祥,刘霆,吴德沛,王健民,王建祥.达沙替尼对中国慢性髓性白血病伊马替尼耐药或不耐受患者疗效及安全性研究[J].中华血液学杂志,2012,33(11):889-895. 被引量:27
  • 3NCCN clinical practice guidelines in oncology:chronic myeloge- nous leukemia [ S/OL ] .Version 2, 2013. http://www.nccn.org/pro- fessionals/physician-gls/f-guidelines.asp#cml.
  • 4中国慢性髓性白血病诊断与治疗指南(2013年版)[J].中华血液学杂志,2013,34(5):464-470. 被引量:92
  • 5荆志成.2010年中国肺高血压诊治指南[J].中国医学前沿杂志(电子版),2011,3(2):62-81. 被引量:117
  • 6Montani D, Seferian A, Savale L, et al. Drug-induced pulmonary arterial hypertension: a recent outbreak [J]. Eur Respir Rev, 2013, 22(29): 244-250.
  • 7Montani D, Bergot E, Giinther S, et al. Pulmonary arterial hyper- tension in patients treated by dasatinib [J]. Circulation, 2012, 125( 17):2128-2137.
  • 8Rasheed W, Flaim B, Seymour JF, et al. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia[J]. Leuk Res, 2009, 33(6): 861-864.
  • 9Mattei D, Feola M, Orzan F, et al. Reversible dasatinib-induced pulmonary arterial hypertension and fight ventricle failure in a previously allografted CML patient [J]. Bone Marrow Trans- plant, 2009, 43( 12): 967-968.
  • 10Hennigs JK, Keller G, Baumann HJ, et al. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmo- nary hypertension?[ J]. BMC Pulm Med, 2011, 11:30.

二级参考文献176

  • 1黄河,蔡真,林茂芳,谢万灼,梁彬,李黎,何静松,罗依,郑伟燕,张洁,叶琇锦,胡晓蓉,陈水云,金爱云.非亲缘异基因骨髓移植治疗儿童白血病[J].中华儿科杂志,2004,42(11):835-839. 被引量:7
  • 2贺其图,时风桐,袁祖正.包头市白血病流行病学调查[J].内蒙古医学杂志,1993,13(2):3-5. 被引量:10
  • 3荆志成.六分钟步行距离试验的临床应用[J].中华心血管病杂志,2006,34(4):381-384. 被引量:98
  • 4江倩,陈珊珊,江滨,江浩,丘镜滢,刘艳荣,张艳,秦亚溱,陆颖,黄晓军,陆道培.甲磺酸伊马替尼治疗慢性粒细胞白血病慢性期100例追踪观察[J].中华血液学杂志,2006,27(11):721-726. 被引量:39
  • 5中华医学会心血管病学分会 中华心血管病杂志编辑委员会.肺动脉高压筛查诊断与治疗专家共识[J].中华心血管病杂志,2007,35:979-987.
  • 6唐正贤 孙秋云 张金桃.上海市金山县11年白血病流行病学调查[J].中华血液学杂志,1994,15(8):430-430.
  • 7Hochhaus A, O' Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia, 2009, 23:1054-1061.
  • 8Ottmann OG, Wassmann B. Treatment of Philadelphia chromo- some-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program, 2005 : 118-122.
  • 9Zonder J, Pemberton P, Brandt H,et al. The effect of dose in- crease of inmtinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res, 2003, 9: 2092-2097.
  • 10Marin D, Goldman JM, Olavarria E, et al. Transient benefit only from increasing the imatinib dose in CML patients who do not a- chieve complete cytogenetic remissions on conventional doses. Blood, 2003, 102:2702-2703.

共引文献227

同被引文献82

  • 1赵阳阳,张启科,曹云山,颜晓菁,伏媛,陈阳,魏小芳,冯友繁.右心导管确诊达沙替尼导致肺动脉高血压1例并文献复习[J].兰州大学学报(医学版),2018,0(5):31-36. 被引量:4
  • 2荆志成.2010年中国肺高血压诊治指南[J].中国医学前沿杂志(电子版),2011,3(2):62-81. 被引量:117
  • 3沈佳坤,金洁.伊马替尼耐药慢性粒细胞白血病的药物治疗[J].世界临床药物,2007,28(8):482-485. 被引量:2
  • 4Deschamps,K.,Matricali,G.A.,Roosen,P,et al.Comparison of foot segmental mobility and coupling during gait between patients with diabetes mellitus with and without neuropathy and adults without diabetes [J].Clinical biomeehanics, 2013,28(7):813-819.
  • 5Richard Wakeford.The risk of leukaemia in young children from exposure to tritium and carbon-14 in the discharges of German nuclear power stations and in the fallout from atmospheric nuclear weapons testing [J].Radiation and En- vironmental Biophysics,2014,53(2):365-379.
  • 6Rasheed W, Flaim B, Seymour JF, et al. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia [ J ]. Leuk Res, 2009, 33 ( 6 ) : 861- 864.
  • 7Mattei D, Feola M, Orzan F, et al. Reversible dasatinib-induced pulmonary arterial hypertension and fight ventricle failure in a previously allografted CML patient[ J ]. Bone Marrow Transplant, 2009, 43(12): 967-968.
  • 8Montani D, Bergot E, GUnther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib [ J ]. Circulation, 2012, 125(17) :2128-2137.
  • 9Hennigs JK, Keller G, Baumann HJ, et al. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? [J]. BMC Pulm Med, 2011, 11:30.
  • 10Dumitrescu D, Seck C, ten Freyhaus H, et al. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia [ J ]. Eur Respir J, 2011, 38 ( 1 ) : 218-220.

引证文献13

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部